Rosenblatt Maintains Buy on Imax, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 67.6%

Neg 0% Neu 0% Pos 67.6%

Rosenblatt analyst Steve Frankel maintains Imax (NYSE:IMAX) with a Buy and raises the price target from $60 to $65.

Comments

No comments yet. Be the first!